ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
Recurrent B Acute Lymphoblastic Leukemia
City of Hope Medical Centerprotein_peptidePhase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 89/ 100
Competitive context
140 Active assets in the Recurrent B Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BBB |
VINCRISTINE SULFATE City of Hope Medical Center | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
Dasatinib National Cancer Institute (NCI) | Phase 3 | BB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →